Arcellx reports positive Phase 2 anito-cel data for relapsed/refractory multiple myeloma at ASH 2024

Arcellx, Inc.

Hosted investor webcast at ASH highlighting new positive data from Phase 2 pivotal iMMagine-1 study of anito-cel.
Study evaluates anitocabtagene autoleucel in patients with relapsed or refractory multiple myeloma.
Filing notes data as positive but does not disclose specific efficacy or safety numbers.
Corporate presentation attached as Exhibit 99.1 provides further details not included in this summary.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.